Skip to main content

Advertisement

SpringerLink
Log in

Pharmacological Management of Osteoporosis in Postmenopausal Women

A Comparative Review

  • Review Article
  • Published:
Drugs & Aging Aims and scope Submit manuscript

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Abstract

Optimising lifestyle and diet are important in the management of osteoporosis, however, they cannot completely prevent postmenopausal bone loss. Calcium supplementation significantly retards but does not completely arrest bone loss, but several small controlled studies suggest that it reduces fracture incidence. Thiazide diuretics slow bone loss similarly but their effects on fracture incidence remain to be determined. Hormone replacement therapy (HRT) increases or maintains bone density, prevents height loss and prevents vertebral fractures. There is observational evidence that HRT decreases cardiovascular disease and increases the risks of thromboembolic disease and breast cancer. The selective estrogen receptor modulator (SERM) raloxifene also slows postmenopausal bone loss although it is less effective that HRT. It also increases the risk of thromboembolic disease but is associated with a significantly reduced risk of breast cancer. The bisphosphonates are of comparable efficacy to HRT in the prevention of bone loss and have been shown to halve the risk of fractures of the vertebrae, forearm and hip. The maintenance of normal vitamin D (colecalciferol) status is important, particularly in the elderly. HRT, the bisphosphonates and raloxifene are all suitable for use in the prevention of postmenopausal bone loss, but the former 2 are to be preferred in the treatment of established disease. The most comprehensive long term safety data are available for HRT. Clinical trials are underway at present with more potent bisphosphonates which may make possible longer dose intervals and alternative routes of administration. There is a need for an effective bone anabolic factor but those which have been trialled to date have not proceeded because of significant adverse effects.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Kameda T, Mano H, Yuasa T, et al. Estrogen inhibits bone resorption by directly inducing apoptosis of the bone-resorbing osteoclasts. J Exp Med 1997; 186: 489–95

    PubMed  CAS  Google Scholar 

  2. Reid IR. Menopause. In: Favus MJ, editor. Primer on metabolic bone diseases and disorders of calcium metabolism. Washington, DC: ASBMR, 1999

    Google Scholar 

  3. Hofbauer LC, Khosla S, Dunstan CR, et al. Estrogen stimulates production of the anti-resorptive cytokine receptor osteo-protegerin in human osteoblastic cells. Bone 1998; 23 Suppl.: S172

    Google Scholar 

  4. Kanis JA, Melton LJ, Christiansen C, et al. Perspective: the diagnosis of osteoporosis. J Bone Miner Res1994; 9: 1137–41

    PubMed  CAS  Google Scholar 

  5. Tinetti ME, Baker DI, McAvay G, et al. A multifactorial intervention to reduce the risk of falling among elderly people living in the community. N Engl J Med 1994; 331: 821–7

    PubMed  CAS  Google Scholar 

  6. Province MA, Hadley EC, Hornbrook MC, et al. The effects of exercise on falls in elderly patients: a preplanned meta-analysis of the FICSIT trials. JAMA 1995; 273: 1341–7

    PubMed  CAS  Google Scholar 

  7. Lauritzen JB, Petersen MM, Lund B. Effect of external hip protectors on hip fractures. Lancet1993; 341: 11–3

    PubMed  CAS  Google Scholar 

  8. Eastell R. Treatment of postmenopausal osteoporosis. N Engl J Med 1998; 338: 736–46

    PubMed  CAS  Google Scholar 

  9. Reid IR. The roles of calcium and vitamin D in the prevention of osteoporosis. Endocrinol Metab Clin North Am 1998; 27(2): 389–98

    PubMed  CAS  Google Scholar 

  10. Recker RR, Hinders S, Davies KM, et al. Correcting calcium nutritional deficiency prevents spine fractures in elderly women. J Bone Miner Res 1996; 11: 1961–6

    PubMed  CAS  Google Scholar 

  11. Devine A, Dick IM, Heal SJ, et al. A 4-year follow-up study of the effects of calcium supplementation on bone density in elderly postmenopausal women. Osteoporos Int 1997; 7: 23–8

    PubMed  CAS  Google Scholar 

  12. Riggs BL, Ofallon WM, Muhs J, et al. Long-term effects of calcium supplementation on serum parathyroid hormone level, bone turnover, and bone loss in elderly women. J Bone Miner Res 1998; 13: 168–74

    PubMed  CAS  Google Scholar 

  13. Dawson-Hughes B, Dallal GE, Krall EA, et al. A controlled trial of the effect of calcium supplementation on bone density in postmenopausal women. N Engl J Med 1990; 323: 878–83

    PubMed  CAS  Google Scholar 

  14. Elders PJ, Netelenbos JC, Lips P, et al. Calcium supplementation reduces vertebral bone loss in perimenopausal women: a controlled trial in 248 women between46 and 55 years of age. J Clin Endocrinol Metab 1991; 73: 533–40

    PubMed  CAS  Google Scholar 

  15. Reid IR, Ames RW, Evans MC, et al. Effect of calcium supplementation on bone loss in postmenopausal women. N Engl J Med 1993; 328: 460–4

    PubMed  CAS  Google Scholar 

  16. Reid IR, Ames RW, Evans MC, et al. Long-term effects of calcium supplementation on bone loss and fractures in postmenopausal women: a randomized controlled trial. Am J Med 1995; 98: 331–5

    PubMed  CAS  Google Scholar 

  17. Reid IR, Schooler BA, Hannon S, et al. The acute biochemical effects of four proprietary calcium supplements. Aust N Z J Med 1986; 16: 193–7

    PubMed  CAS  Google Scholar 

  18. Chevalley T, Rizzoli R, Nydegger V, et al. Effects of calcium supplements on femoral bone mineral density and vertebral fracture rate in vitamin-D-replete elderly patients. Osteoporos Int 1994; 4: 245–52

    PubMed  CAS  Google Scholar 

  19. Nieves JW, Komar L, Cosman F, et al. Calcium potentiates the effect of estrogen and calcitonin on bone mass: review and analysis. Am J Clin Nutr 1998; 67: 18–24

    PubMed  CAS  Google Scholar 

  20. Ettinger B, Genant HK, Cann CE. Postmenopausal bone loss is prevented by treatment with low-dosage estrogen with calcium. Ann Intern Med 1987; 106: 40–5

    PubMed  CAS  Google Scholar 

  21. Davis JW, Ross PD, Johnson NE, et al. Estrogen and calcium supplement use among Japanese-American women: effects upon bone loss when used singly and in combination. Bone 1995; 17: 369–73

    PubMed  CAS  Google Scholar 

  22. Curhan GC, Willett WC, Speizer FE, et al. Comparison of dietary calcium with supplemental calcium and other nutrients as factors affecting the risk for kidney stones in women. Ann Intern Med 1997; 126(7): 497–504

    PubMed  CAS  Google Scholar 

  23. Malabanan A, Veronikis IE, Holick MF. Redefining vitamin D insufficiency. Lancet 1998; 351: 805–6

    PubMed  CAS  Google Scholar 

  24. Ooms ME, Roos JC, Bezemer PD, et al. Prevention of bone loss by vitamin D supplementation in elderly women: a randomized double-blind trial. J Clin Endocrinol Metab 1995; 80: 1052–8

    PubMed  CAS  Google Scholar 

  25. Dawson-Hughes B, Harris SS, Krall EA, et al. Rates of bone loss in postmenopausal women randomly assigned to one of two dosages of vitamin D. Am J Clin Nutr 1995; 61: 1140–5

    PubMed  CAS  Google Scholar 

  26. Lips P, Graafmans WC, Ooms ME, et al. Vitamin D supplementation and fracture incidence in elderly persons: a randomized, placebo-controlled clinical trial. Ann Intern Med 1996; 124: 400–6

    PubMed  CAS  Google Scholar 

  27. Heikinheimo RJ, Inkovaara JA, Harju EJ, et al. Annual injection of vitamin D and fractures of aged bones. Calcif Tissue Int 1992; 51: 105–10

    PubMed  CAS  Google Scholar 

  28. Chapuy MC, Arlot ME, Duboeuf F, et al. Vitamin-D3 and calcium to prevent hip fractures in elderly women. N Engl J Med 1992; 327: 1637–42

    PubMed  CAS  Google Scholar 

  29. Chapuy MC, Arlot ME, Delmas PD, et al. Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women. BMJ 1994; 308: 1081–2

    PubMed  CAS  Google Scholar 

  30. Dawson-Hughes B, Harris SS, Krall EA, et al. Effect of calcium and vitamin D supplementation on bone, density in men and women 65 years of age or older. N Engl J Med 1997; 337: 670–6

    PubMed  CAS  Google Scholar 

  31. Komulainen M, Tuppurainen MT, Kroger H, et al. Vitamin D and HRT — no benefit additional to that of HRT alone in prevention of bone loss in early postmenopausal women: a 2.5-year randomized placebo-controlled study. Osteoporos Int 1997; 7: 126–32

    PubMed  CAS  Google Scholar 

  32. Christiansen C, Christensen MS, McNair P, et al. Prevention of early postmenopausal bone loss: controlled 2-year study in 315 normal females. Eur J Clin Invest 1980; 10: 273–9

    PubMed  CAS  Google Scholar 

  33. Nordin BEC, Horsman A, Crilly RG, et al. Treatment of spinal osteoporosis in postmenopausal women. BMJ 1980; 1: 451–4

    Google Scholar 

  34. Lindsay R, Hart DM, Forrest C, et al. Prevention of spinal osteoporosis in oophorectomised women. Lancet 1980; II: 1151–3

    Google Scholar 

  35. Lindsay R. Prevention and treatment of osteoporosis with ovarian hormones. Ann Chir Gynaecol 1988; 77: 219–23

    PubMed  CAS  Google Scholar 

  36. Hosking D, Chilvers CED, Christiansen C, et al. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. N Engl J Med 1998; 338: 485–92

    PubMed  CAS  Google Scholar 

  37. Bush TL, Wells HB, James MK, et al. Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. JAMA 1996; 276: 1389–96

    Google Scholar 

  38. Jensen GF, Christiansen C, Transbol I. Treatment of post menopausal osteoporosis: a controlled therapeutic trial comparing oestrogen/gestagen, 1,25-dihydroxy-vitamin D3 and calcium. Clin Endocrinol 1982; 16: 515–24

    CAS  Google Scholar 

  39. Lufkin EG, Wahner HW, O’Fallon WM, et al. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med 1992; 117: 1–9

    PubMed  CAS  Google Scholar 

  40. Lufkin EG, Riggs BL. Three-year follow-up on effects of transdermal estrogen [letter]. Ann Intern Med 1996; 125(1): 77

    PubMed  CAS  Google Scholar 

  41. Grey AB, Cundy TF, Reid IR. Continuous combined oestrogen/progestin therapy is well tolerated and increases bone density at the hip and spine in post-menopausal osteoporosis. Clin Endocrinol 1994; 40: 671–7

    CAS  Google Scholar 

  42. Cauley JA, Seeley DG, Ensrud K, et al. Estrogen replacement therapy and fractures in older women. Ann Intern Med 1995; 122: 9–16

    PubMed  CAS  Google Scholar 

  43. Michaelsson K, Baron JA, Farahmand BY, et al. Hormone replacement therapy and risk of hip fracture: population based case-control study. BMJ 1998; 316: 1858–63

    PubMed  CAS  Google Scholar 

  44. Lafferty FW, Fiske ME. Postmenopausal estrogen replacement: a long-term cohort study. Am J Med 1994; 97: 66–77

    PubMed  CAS  Google Scholar 

  45. Naessen T, Persson I, Thor L, et al. Maintained bone density at advanced ages after long term treatment with low dose oestradiol implants. Br J Obstet Gynaecol 1993; 100: 454–9

    PubMed  CAS  Google Scholar 

  46. Christiansen C, Christensen MS, Transbol I. Bone mass in postmenopausal women after withdrawal of oestrogen/gestagen replacement therapy. Lancet 1981; I: 459–61

    Google Scholar 

  47. Felson DT, Zhang YQ, Hannan MT, et al. The effect of postmenopausal estrogen therapy on bone density in elderly women. N Engl J Med 1993; 329: 1141–6

    PubMed  CAS  Google Scholar 

  48. Schneider DL, Barrett-Connor EL, Morton DJ. Timing of postmenopausal estrogen for optimal bone mineral density: the Rancho Bernardo study. JAMA 1997; 277: 543–7

    PubMed  CAS  Google Scholar 

  49. Grey A, Cundy T, Evans M, et al. Medroxyprogesterone acetate enhances the spinal bone mineral density response to oestrogen in late post-menopausal women. Clin Endocrinol 1996; 44: 293–6

    CAS  Google Scholar 

  50. Speroff L, Rowan J, Symons J, et al. The comparative effect on bone density, endometrium, and lipids of continuous hormones as replacement therapy (CHART Study): a randomized controlled trial. JAMA 1996; 276: 1397–403

    PubMed  CAS  Google Scholar 

  51. Bjarnason NH, Bjarnason K, Haarbo J, et al. Tibolone: prevention of bone loss in late postmenopausal women. J Clin Endocrinol Metab 1996; 81: 2419–22

    PubMed  CAS  Google Scholar 

  52. Wimalawansa SJ. Combined therapy with estrogen and etidronate has an additive effect on bone mineral density in the hip and vertebrae: four-year randomized study. Am J Med 1995; 99: 36–42

    PubMed  CAS  Google Scholar 

  53. Wimalawansa SJ. A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis. Am J Med 1998; 104: 219–26

    PubMed  CAS  Google Scholar 

  54. Lindsay R, Cosman F, Cary DJ, et al. Effect of alendronate added to ongoing hormone replacement therapy on the bone mineral density of women with postmenopausal osteoporosis. Bone 1998; 23 Suppl.: S597

    Google Scholar 

  55. Gutteridge DH, Holzherr M, Will R, et al. Postmenopausal vertebral fractures: advantage of HRT plus calcitriol, over HRT alone, attotal body and hip in malabsorbers and normal absorbers of Ca. Bone 1998; 23 Suppl.: S527

    Google Scholar 

  56. Alexandersen P, Hassager C, Sandholdt I, et al. Synergistic effect of hormone replacement therapy combined with monofluorophosphate on bone mass in late postmenopausal women. J Bone Miner Res 1997; 12Suppl. 1: S104

    Google Scholar 

  57. Barrettconnor E, Grady D. Hormone replacement therapy, heart disease, and other considerations. Annu Rev Public Health 1998; 19: 55–72

    CAS  Google Scholar 

  58. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998; 280: 605–13

    PubMed  CAS  Google Scholar 

  59. Beral V, Bull D, Doll R, et al. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997; 350: 1047–59

    Google Scholar 

  60. Love RR, Mazess RB, Barden HS, et al. Effects of tamoxifen on bone mineral content in postmenopausal women with breast cancer. N Engl J Med 1991; 326: 852–6

    Google Scholar 

  61. Grey AB, Stapleton JP, Evans MC, et al. The effect of the anti-estrogen tamoxifen on cardiovascular risk factors in normal postmenopausal women. J Clin Endocrinol Metab 1995; 80: 3191–5

    PubMed  CAS  Google Scholar 

  62. Grey AB, Stapleton JP, Evans MC, et al. The effect of the anti estrogen tamoxifen on bone mineral density in normal late postmenopausal women. Am J Med 1995; 99: 636–41

    PubMed  CAS  Google Scholar 

  63. Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997; 337: 1641–7

    PubMed  CAS  Google Scholar 

  64. Lufkin EG, Whitaker MD, Nickelsen T, et al. Treatment of established postmenopausal osteoporosis with raloxifene: a randomized. J Bone Miner Res 1998; 13: 1747–54

    PubMed  CAS  Google Scholar 

  65. Ettinger B, Black DM, Mitlak BH, et al. Reduction in vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. JAMA1999; 282: 637–45

    PubMed  CAS  Google Scholar 

  66. Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk ofbreast cancer in postmenopausal women: results from the MORE randomized trial. JAMA 1999; 281: 2189–97

    PubMed  CAS  Google Scholar 

  67. Luckman SP, Hughes DE, Coxon FP, et al. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of gtp-binding proteins, including ras. J Bone Miner Res 1998; 13: 581–9

    PubMed  CAS  Google Scholar 

  68. Ebetino FH, Francis MD, Rogers MJ, et al. Mechanisms of action of etidronate and other bisphosphonates. Rev Cont Pharmacother 1998; 9: 233–43

    CAS  Google Scholar 

  69. Reid IR, King AR, Alexander CJ, et al. Prevention of steroid-induced osteoporosis with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD). Lancet 1988; I: 143–6

    Google Scholar 

  70. Storm T, Thamsborg G, Steiniche T, et al. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in postmenopausal osteoporosis. N Engl J Med 1990; 322: 1265–71

    PubMed  CAS  Google Scholar 

  71. Watts NB, Harris ST, Genant HK, et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 1990; 323: 73–9

    PubMed  CAS  Google Scholar 

  72. Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995; 333: 1437–43

    PubMed  CAS  Google Scholar 

  73. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996; 348: 1535–41

    PubMed  CAS  Google Scholar 

  74. Chavassieux PM, Arlot ME, Reda C, et al. Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 1997; 100: 1475–80

    PubMed  CAS  Google Scholar 

  75. Lufkin EG, Argueta R, Whitaker MD, et al. Pamidronate: an unrecognized problem in gastrointestinal tolerability. Osteoporos Int 1994; 4: 320–2

    PubMed  CAS  Google Scholar 

  76. Degroen PC, Lubbe DF, Hirsch LJ, et al. Esophagitis associated with the use of alendronate. N Engl J Med 1996; 335: 1016–21

    CAS  Google Scholar 

  77. Graham DY, Malaty HM, Goodgame R. Primary aminobisphosphonates: a new class of gastrotoxic drugs — comparison of alendronate and aspirin. Am J Gastroenterol 1997; 92: 1322–5

    PubMed  CAS  Google Scholar 

  78. Mackay FJ, Wilton LV, Pearce GL, et al. United Kingdom experience with alendronate and oesophageal reactions. Br J Gen Pract 1998; 48: 1161–2

    PubMed  CAS  Google Scholar 

  79. Jones G, Nguyen T, Sambrook PN, et al. Thiazide diuretics and fractures: can meta-analysis help? J Bone Miner Res 1995; 10: 106–11

    PubMed  CAS  Google Scholar 

  80. LaCroix Z, Ott SM, Ichikawa LE, et al. Low dose thiazide prevents bone loss in older adults: results of a 3-yearrandomized, double-blind controlled trial. Bone 1998; 23 Suppl.: S151

    Google Scholar 

  81. Reid IR, Ames RW, Orr-Walker BJ, et al. Hydrochlorothiazide reduces loss of cortical bone in normal postmenopausal women: a randomized controlled trial. Bone 1998; 23 Suppl.: S584

    Google Scholar 

  82. Christiansen C, Christensen MS, Rodbro P, et al. Effect of 1,25-dihydroxy-vitamin D3 in itself or combined with hormone treatment in preventing postmenopausal osteoporosis. Eur J Clin Invest 1981; 11: 305–9

    PubMed  CAS  Google Scholar 

  83. Jensen GF, Meinecke B, Boesen J, et al. Does 1,25(OH)2 D3 accelerate spinal bone loss? Clin Orthop 1985; 192: 215–21

    PubMed  Google Scholar 

  84. Falch JA, Odegaard OR, Finnanger M, et al. Postmenopausal osteoporosis: no effect of three years treatment with 1,25-dihydroxycholecalciferol. Acta Med Scand 1987; 221: 199–204

    PubMed  CAS  Google Scholar 

  85. Ott SM, Chesnut CH. Calcitriol treatment is not effective in postmenopausal osteoporosis. Ann Intern Med 1989; 110: 267–74

    PubMed  CAS  Google Scholar 

  86. Gallagher JC, Goldgar D. Treatment of postmenopausal osteoporosis with high doses of synthetic calcitriol: a randomized controlled study. Ann Intern Med 1990; 113: 649–55

    PubMed  CAS  Google Scholar 

  87. Aloia JF, Vaswani A, Yeh JK, et al. Calcitriol in the treatment of postmenopausal osteoporosis. Am J Med 1988; 84: 401–8

    PubMed  CAS  Google Scholar 

  88. Tilyard MW, Spears GF, Thomson J, et al. Treatment of postmenopausal osteoporosis with calcitriol or calcium. N Engl J Med 1992; 326: 357–62

    PubMed  CAS  Google Scholar 

  89. Reid IR. Vitamin D and its metabolites in the management of osteoporosis. In: Marcus R, Feldman D, Kelsey J, editors. Osteoporosis. San Diego (CA): Academic Press, 1996

    Google Scholar 

  90. Luisetto G, Bottega F, Zangari M, et al. Effects of three therapeutic regimens on postmenopausal bone loss in oophorectomized women. Curr Ther Res Clin Exp 1996; 57: 839–48

    CAS  Google Scholar 

  91. Itoi H, Minakami H, Sato I. Comparison of the long-term effects of oral estriol with the effects of conjugated estrogen, 1-alphahydroxyvitamin d-3 and calcium lactate on vertebral bone loss in early menopausal women. Maturitas 1997; 28: 11–7

    PubMed  CAS  Google Scholar 

  92. Frediani B, Allegri A, Bisogno S, et al. Effects of combined treatment with calcitriol plus alendronate on bone mass and bone turnover in postmenopausal osteoporosis two years of continuous treatment. Clin Drug Invest 1998; 15: 235–44

    CAS  Google Scholar 

  93. Masud T, Mulcahy B, Thompson AV, et al. Effects of cyclical etidronate combined with calcitriol versus cyclical etidronate alone on spine and femoral neck bone mineral density in postmenopausal osteoporotic women. Ann Rheum Dis 1998; 57: 346–9

    PubMed  CAS  Google Scholar 

  94. Eddy DM, Johnston CC, Cummings SR, et al. Osteoporosis: review of the evidence for prevention, diagnosis, and treatment and cost-effectiveness analysis. Osteoporos Int 1998; 8Suppl. 4: 1–88

    Google Scholar 

  95. Arnala I, Saastamoinen J, Alhava EM. Salmon calcitoninin the prevention of bone loss at perimenopause. Bone 1996; 18: 629–32

    PubMed  CAS  Google Scholar 

  96. Stock JL, Avioli LV, Baylink DJ, et al. Calcitonin-salmon nasal spray reduces the incidence of new vertebral fractures in postmenopausal women: three year interim results of the PROOF study. J Bone Miner Res 1997; 12Suppl. 1: S149

    Google Scholar 

  97. Silverman SL, Chesnut C, Andriano K, et al. Salmon calcitonin nasalspray(NS-CT)reduces risk of vertebral fracture(s)(VF) in established osteoporosis and has continuous efficacy with prolonged treatment: accrued 5 year worldwide data of the PROOF study. Bone 1998; 23 Suppl.: S174

    Google Scholar 

  98. Riggs BL, Hodgson SF, O’Fallon WM, et al. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med 1990; 322: 802–9

    PubMed  CAS  Google Scholar 

  99. Caverzasio J, Imai T, Ammann P, et al. Aluminum potentiates the effect of fluoride on tyrosine phosphorylation and osteoblast replication in vitro and bone mass in vivo. J Bone Miner Res 1996; 11: 46–55

    PubMed  CAS  Google Scholar 

  100. Meunier PJ, Sebert JL, Reginster JY, et al. Fluoride salts are no better at preventing new vertebral fractures than calcium-vitamin D in postmenopausal osteoporosis: the Favos study. Osteoporos Int 1998; 8: 4–12

    PubMed  CAS  Google Scholar 

  101. Pak CYC, Sakhaee K, Adamshuet B, et al. Treatment of postmenopausal osteoporosis with slow-release sodium fluoride: final report of a randomized controlled trial. Ann Intern Med 1995; 123: 401–8

    PubMed  CAS  Google Scholar 

  102. Reginster JY, Meurmans L, Zegels B, et al. The effect of sodium monofluorophosphate plus calcium on vertebral fracture rate in postmenopausal women with moderate osteoporosis: a randomized, controlled trial. Ann Intern Med 1998; 129(1): 1–8

    PubMed  CAS  Google Scholar 

  103. Need AG, Horowitz M, Bridges A, et al. Effects of nandrolone decanoate and antiresorptive therapy on vertebral density in osteoporotic postmenopausal women. Arch Int Med 1989; 149: 57–60

    CAS  Google Scholar 

  104. Reid IR, Wattie DJ, Evans MC, et al. Continuous therapy with pamidronate,apotentbisphosphonate,in postmenopausal osteoporosis. J Clin Endocrinol Metab 1994; 79: 1595–9

    PubMed  CAS  Google Scholar 

  105. Cornish J, Callon KE, King AR, et al. Systemic administration of amylin increases bone mass, linear growth, and adiposity in adult male mice. Am J Physiol 1998; 38: E694–9

    Google Scholar 

  106. Mundy G, Gutteriez G, Garrett R, et al. Identification of a new class of powerful stimulators of new bone formation in vivo, clarification of mechanism of action, and use in animal models of osteoporosis. Bone 1998; 23 Suppl.: S183

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, University of Auckland, Private Bag 92019, Auckland, New Zealand

    Ian R. Reid

Authors
  1. Ian R. Reid
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ian R. Reid.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Reid, I.R. Pharmacological Management of Osteoporosis in Postmenopausal Women. Drugs Aging 15, 349–363 (1999). https://doi.org/10.2165/00002512-199915050-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-199915050-00003

Keywords

Search

Navigation